Private equity (PE) investors are betting on Indian drug makers that manufacture active pharmaceutical ingredients (APIs), even as uncertainty over covid-19 has slowed down investments.
Continue reading this premium story with a subscription to DealStreetAsia.
SubscribeAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
